Tanerasertib

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable covalent inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, with potential antineoplastic activity. Upon oral administration, tanerasertib targets, allosterically binds to and inhibits AKT1 E17K. This may inhibit growth of and induce apoptosis in AKT1 E17K-driven cancers. AKT1 E17K, overexpressed in a variety of cancer cell types, drives cancer cell proliferation. By specifically targeting the E17K mutant variant, tanerasertib may avoid the toxicities associated with wild-type (WT) AKT inhibition.

**Synonyms:** - AKT1 E17K Inhibitor ALTA2618 - AKT1 E17K-mutant Inhibitor ALTA2618 - ALTA 2618 - ALTA-2618 - ALTA2618 - Mutant-selective AKT1 Inhibitor ALTA2618 - TANERASERTIB